MissionIR Articles

Life sciences company VolitionRx is engaged in the development of blood-based diagnostic tests for different types of cancer. Demonstrating significant headway with its NuQ® assays, VolitionRx recently released data from a pilot study of the…

Earlier this week, VolitionRx reported significant results from a pilot study of use of its NuQ® tests for diagnosis of prostate cancer. The results of the trial showed that the tests were able to detect…

VolitionRx is a publicly traded life sciences company focused on the development of blood-based diagnostics for different types of cancer. It believes that current diagnostic measures are too costly or inadequate, and to that end…

For those of you who are interested in investing in speculative growth with biotech stocks, the potential of a test or drug that can be brought to market makes all the difference. I have been…

VolitionRx, a life sciences company, announced today that it has completed a private placement with select new and existing accredited investors and received $3 million in gross proceeds from the transaction. Lake Street Capital Markets,…

Early detection of cancer increases the chance of survival and/or curative treatment. While this is true of all cancers, the World Health Organization puts emphasis on the value of early diagnosis in cancers of the…

VolitionRx is a publicly traded life sciences company that is developing innovative solutions for blood-based diagnostics for different types of cancers. The company believes that current diagnostics techonologies are inadequate, so is focusing its efforts…

VolitionRx is a biotech small-cap dedicated to the development of blood-based diagnostic tests for different types of cancer, with an initial focus on colorectal cancer, the second deadliest cancer in the United States. After the…

VolitionRx was one of two companies recently highlighted in an article published in Wall St. Cheat Sheet that emphasized the long-term impact of positive news and/or achievements in the biotechnology industry. “One way to offset…

The early detection of cancer is considered crucial in developing a truly effective approach to dealing with the disease. There are, of course, many types of cancers, but early detection, before symptoms develop, could have…

Today before the opening bell, VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, announced it has commenced blood sample analysis for its largest clinical study to…

VolitionRx, an ambitious life sciences company, wants to make non-invasive blood tests for cancer as commonplace and easy to use as current blood tests for diabetes and high cholesterol. With only one blood test for…

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, this morning told investors that the company presented at the 2nd annual MicroCapClub Invitational. The company’s presentation can…

Today before the opening bell, MissionIR announced that a new audio interview with VolitionRx, Ltd. (OTCQB: VNRX) President and CEO Cameron Reynolds had been published online. The entirety of the interview can be found at:…

VolitionRx is developing two types of non-invasive cancer diagnostic tests based on its patented Nucleosomics® technology. The company’s overarching goal is to bring to market its cancer blood tests and revolutionize cancer diagnosis. While VolitionRx’s…

Today, shortly after the opening bell, VolitionRx announced that it has engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence…